# Neuralink Corp. — Healthcare Investment Intelligence

> other · Series C+. MedFuel Intel profile as of 2026-06-12.

Neuralink is developing implantable brain-computer interfaces (BCIs) for treating brain diseases and human enhancement. By 2019, it had raised $158 million in funding, including $100 million from Elon Musk, indicating Series C+ stage, with ongoing human clinical trials as of 2025.

## Key facts (as of 2026-06-12)
- Sector: other
- Stage: Series C+
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-13. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.